Literature DB >> 19907150

The natural history of untreated HFE-related hemochromatosis.

Paul C Adams1.   

Abstract

Hemochromatosis has generally been considered to be a genetic disease in which progressive iron accumulation over many years can lead to cirrhosis of the liver, hepatocellular carcinoma, diabetes, cardiomyopathy, and arthropathy. Iron depletion by phlebotomy has been the recommended therapy although a randomized trial of phlebotomy versus no treatment has never been reported. Since the discovery of the HFE gene in 1996, it has been possible to predict the risk of developing iron overload by a simple blood test to detect C282Y homozygotes of the HFE gene. The application of the hemochromatosis genetic test in large population studies often initiated to investigate other diseases has provided a fascinating glimpse into the natural history of untreated C282Y homozygotes followed for over 20 years without phlebotomy treatment. These observations are summarized in this review article which raises questions about the need for phlebotomy in all C282Y homozygous patients. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19907150     DOI: 10.1159/000243797

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  7 in total

1.  H63D genotying for hemochromatosis: helper or hindrance?

Authors:  Paul C Adams
Journal:  Can J Gastroenterol Hepatol       Date:  2014-04

2.  Survival and development of health conditions after iron depletion therapy in C282Y-linked hemochromatosis patients.

Authors:  Paul C Adams; Lucie Richard; Matthew Weir; Mark Speechley
Journal:  Can Liver J       Date:  2021-11-11

3.  A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.

Authors:  Pradyumna Phatak; Pierre Brissot; Mark Wurster; Paul C Adams; Herbert L Bonkovsky; John Gross; Peter Malfertheiner; Gordon D McLaren; Claus Niederau; Alberto Piperno; Lawrie W Powell; Mark W Russo; Ulrich Stoelzel; Wolfgang Stremmel; Louis Griffel; Nicola Lynch; Yiyun Zhang; Antonello Pietrangelo
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

Review 4.  Twenty-Five Years of Contemplating Genotype-Based Hereditary Hemochromatosis Population Screening.

Authors:  Jörg Schmidtke
Journal:  Genes (Basel)       Date:  2022-09-09       Impact factor: 4.141

5.  Genetic effects of iron levels on liver injury and risk of liver diseases: A two-sample Mendelian randomization analysis.

Authors:  Kai Wang; Fangkun Yang; Pengcheng Zhang; Yang Yang; Li Jiang
Journal:  Front Nutr       Date:  2022-09-16

Review 6.  Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes.

Authors:  Scott D Grosse; Lyle C Gurrin; Nadine A Bertalli; Katrina J Allen
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822

7.  EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH).

Authors:  Graça Porto; Pierre Brissot; Dorine W Swinkels; Heinz Zoller; Outi Kamarainen; Simon Patton; Isabel Alonso; Michael Morris; Steve Keeney
Journal:  Eur J Hum Genet       Date:  2015-07-08       Impact factor: 4.246

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.